Tempest Therapeutics, Inc. Repayments of Debt
Tempest Therapeutics, Inc. (TPST) reported Repayments of Debt of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2026-08-13
- Tempest Therapeutics, Inc. repayments of debt for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. repayments of debt for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. repayments of debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. repayments of debt for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. repayments of debt for fiscal 2025 was $6.43M, a 46.11% increase from fiscal 2024.
- Tempest Therapeutics, Inc. repayments of debt for fiscal 2024 was $4.40M.
- Tempest Therapeutics, Inc. repayments of debt for fiscal 2022 was $4.74M.
- Tempest Therapeutics, Inc. repayments of debt for fiscal 2020 was $108.00K, a 41.30% decline from fiscal 2019.
| Period end | Repayments of Debt | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | $4.23M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $4.23M derived: sum of 3 quarters · filed 2026-08-13 | $6.43M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.23M derived: sum of 2 quarters · filed 2026-08-13 | $6.43M 10-Q · filed 2025-11-05 | $8.63M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $4.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.43M 10-Q · filed 2026-08-13 | $8.63M derived: sum of 3 quarters · filed 2026-08-13 | $10.82M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-04-08 | $3.50M 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | $2.20M 10-Q · filed 2026-05-14 | $4.40M derived: sum of 2 quarters · filed 2026-05-14 | $6.60M derived: sum of 3 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.40M derived: sum of 2 quarters · filed 2026-03-30 | $4.40M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.20M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-11 | ||||
| 2022-12-31 | $4.74M 10-K · filed 2024-03-19 | ||||
| 2021-03-31 | $54.00K 10-Q · filed 2021-05-13 | $109.00K derived: sum of 2 quarters · filed 2021-05-13 | $162.00K derived: sum of 3 quarters · filed 2021-05-13 | $162.00K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2020-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $108.00K derived: sum of 2 quarters · filed 2021-03-29 | $108.00K derived: sum of 3 quarters · filed 2021-03-29 | $108.00K 10-K · filed 2021-03-29 | |
| 2020-09-30 | $53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $53.00K derived: sum of 2 quarters · filed 2020-11-09 | $53.00K 10-Q · filed 2020-11-09 | $103.00K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | $50.00K derived: sum of 3 quarters · filed 2021-05-13 | $94.00K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 | $50.00K derived: sum of 2 quarters · filed 2021-05-13 | $94.00K derived: sum of 3 quarters · filed 2021-05-13 | $139.00K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $94.00K derived: sum of 2 quarters · filed 2021-03-29 | $139.00K derived: sum of 3 quarters · filed 2021-03-29 | $184.00K 10-K · filed 2021-03-29 | |
| 2019-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $89.00K derived: sum of 2 quarters · filed 2020-11-09 | $134.00K 10-Q · filed 2020-11-09 | $178.00K derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $90.00K 10-Q · filed 2020-08-10 | $134.00K derived: sum of 3 quarters · filed 2020-08-10 | $175.00K derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $45.00K 10-Q · filed 2020-05-08 | $89.00K derived: sum of 2 quarters · filed 2020-05-08 | $130.00K derived: sum of 3 quarters · filed 2020-05-08 | $171.00K derived: sum of 4 quarters · filed 2020-05-08 | |
| 2018-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $85.00K derived: sum of 2 quarters · filed 2019-11-13 | $126.00K derived: sum of 3 quarters · filed 2019-11-13 | $169.00K 10-K · filed 2019-04-01 | |
| 2018-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $82.00K derived: sum of 2 quarters · filed 2019-11-13 | $125.00K 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $84.00K 10-Q · filed 2019-08-12 | |||
| 2018-03-31 | $43.00K 10-Q · filed 2019-05-15 | ||||
| 2017-12-31 | $10.04M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |